Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer This phase Ib study evaluated the safety and efficacy of paclitaxel plus navicixizumab, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results